Loading the security overview…
Where the tokens are
Trade MRNA perps| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 7, 2026 | −$1.97 | — | $145.00M | +2.1% | −$2.12 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | −$3.40 | — | $389.00M | +260.2% | −$2.03 |
| Q4 FY25ended Dec 31, 2025 | — | −$2.11 | — | $678.00M | −29.8% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.51 | −1800.0% | $1.02B | −45.4% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$2.13 | — | $142.00M | −41.1% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$2.52 | — | $108.00M | −35.3% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$3.02 | −603.3% | $966.00M | −65.6% | — |
| Q3 FY24ended Sep 30, 2024 | — | $0.03 | — | $1.86B | +1.7% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Moderna shares, not any token. As of Aug 7, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 | — | −$3.33 | — | $241.00M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$3.07 | — | $167.00M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.60 | — | $2.81B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$9.53 | — | $1.83B | — | — |